Benadryl® / ZzzQuil® / Unisom®
Diphenhydramine HCl
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$5–12
With Insurance
$3–10 (OTC)
How It Works
Diphenhydramine is a first-generation H1 antihistamine that blocks histamine from binding to H1 receptors across multiple tissues — reducing the allergic cascade (itching, mucus, sneezing, hives). Its defining pharmacological problem is that it crosses the blood-brain barrier easily — unlike second-generation antihistamines (loratadine, cetirizine) which do not. Inside the brain, it blocks not just H1 receptors but also muscarinic acetylcholine receptors, alpha-1 adrenergic receptors, and serotonin receptors. This broad receptor "carpet bombing" is the source of every serious side effect: the muscarinic blockade causes the classic anticholinergic toxidrome (dry mouth, urinary retention, constipation, blurred vision, confusion, delirium) and — with chronic exposure — reduces cholinergic neurotransmission in the hippocampus, which is implicated in the dementia risk documented by Gray et al. (2015). The "sleep benefit" is purely the CNS H1 and muscarinic blockade causing sedation — it disrupts normal sleep architecture (suppresses REM) rather than facilitating natural sleep. Tolerance to this sedation develops in 3–4 nights in most users.
Why the side effects happen
The sedation comes from blocking wake-promoting H1 and muscarinic receptors in the brain — not from promoting sleep architecture. REM sleep is suppressed. Urinary retention occurs because muscarinic receptors are required to contract the bladder detrusor muscle — block them and the bladder cannot empty, which is why men with enlarged prostates can go into acute retention. The dementia link (Gray et al. 2015: 54% increased risk with cumulative strong anticholinergic use) is thought to reflect chronic reduction of acetylcholine neurotransmission in hippocampal circuits essential for memory formation — compounding normal age-related cholinergic decline. Tolerance to the sleep sedation (but NOT the anticholinergic side effects) develops within 3–4 nights.
When Will I Feel It?
Diphenhydramine works within 15–30 minutes for allergy symptoms. Sleep sedation peaks at 1–3 hours. Tolerance to the sleep effect develops within 3–4 nights. Anticholinergic side effects are present from the first dose onward.
Allergy symptom relief begins — histamine blocked at peripheral H1 receptors. Sedation and dry mouth also begin within this window.
Peak plasma levels — maximum sedation. Do not drive or operate machinery. Urinary retention risk highest in this window.
Sleep sedation tolerance established — drug no longer improves sleep onset meaningfully. Anticholinergic side effects persist without tolerance.
Residual "hangover" sedation impairs driving, cognitive performance, and reaction time — especially at 50mg dose and in older adults. Half-life is 4–8 hours but CNS effects linger longer.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Sedation / drowsiness
70%+The "sleep benefit" is sedation, not true sleep — REM architecture is disrupted. Tolerance to sleep effects develops in 3–4 nights.
Dry mouth
35%+Anticholinergic effect — chew sugarless gum; stay hydrated; can worsen dental cavities with long-term use
Urinary retention
High in men with BPHMen with enlarged prostate may be unable to urinate. Seek immediate medical care if you cannot urinate after taking.
Constipation
20%Anticholinergic effect — ensure adequate fiber and water; avoid in patients with bowel motility issues
Blurred vision
10–15%Anticholinergic pupil dilation — do not drive if vision is affected; avoid in narrow-angle glaucoma (can precipitate acute angle-closure crisis)
Next-day cognitive "hangover"
Common with 50mgResidual sedation impairs driving and cognition the next morning — especially at the 50mg sleep dose; start at 25mg
Paradoxical excitation (children)
5–10% of childrenSome children become hyperactive, agitated, and restless rather than sedated — stop use and do not readminister if this occurs
Serious Adverse Effects
- • Anticholinergic delirium in elderly — confusion, agitation, hallucinations, disorientation; can be life-threatening if not recognized
- • Acute urinary retention — may require catheterization; risk highest in men with BPH
- • Acute narrow-angle glaucoma crisis — sudden severe eye pain, blurred vision, halos; stop immediately and seek emergency care
- • Cumulative dementia risk — Gray et al. (2015): 54% increased risk with long-term cumulative anticholinergic use
- • Falls and fractures in elderly — sedation + postural hypotension significantly increases fall risk
- • Severe respiratory depression with opioids or alcohol — has contributed to overdose deaths
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Anticholinergic delirium in elderly — confusion, agitation, hallucinations, disorientation; can be life-threatening if not recognized
- Acute urinary retention — may require catheterization; risk highest in men with BPH
- Acute narrow-angle glaucoma crisis — sudden severe eye pain, blurred vision, halos; stop immediately and seek emergency care
- Cumulative dementia risk — Gray et al. (2015): 54% increased risk with long-term cumulative anticholinergic use
- Inability to urinate — stop immediately and seek emergency care
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Some studies suggest associations with birth defects in the first trimester — evidence is mixed but the precautionary principle applies. Avoid non-essential use. Short-term occasional use later in pregnancy likely low risk but discuss with your provider.
Diphenhydramine passes into breast milk and can cause sedation and respiratory depression in nursing infants, particularly newborns. Avoid. Loratadine (Claritin) is the preferred antihistamine for nursing mothers.
Post-menopausal estrogen decline already accelerates cognitive changes. Adding a high-anticholinergic drug like diphenhydramine compounds this risk. The Gray et al. 2015 dementia study's highest-risk group were women over 65 using strong anticholinergics regularly. Safer options for allergy: loratadine. For sleep: melatonin 0.5mg + sleep hygiene.
FDA 2008 warning: not for use in children under 2 years — risk of fatal respiratory depression. Under 12: weight-dose carefully; paradoxical excitation in 5–10%; monitor closely. Diphenhydramine is NOT appropriate as a child sleep aid — risk vs. no benefit.
The American Geriatrics Society Beers Criteria explicitly lists all first-generation antihistamines including diphenhydramine as HIGH RISK in adults ≥65. Reasons: anticholinergic delirium, fall risk, cognitive impairment, urinary retention, and cumulative dementia association. Use is strongly discouraged — switch to loratadine or cetirizine for allergies; use melatonin 0.5–1mg for sleep.
Diphenhydramine is renally cleared — reduced kidney function leads to drug accumulation, prolonged sedation, and higher anticholinergic toxicity risk.
Hepatically metabolized — impaired liver function increases exposure. Avoid regular use in significant hepatic impairment.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Allergy & Sleep Without Anticholinergic Risk
For allergies, second-generation antihistamines (loratadine, cetirizine, fexofenadine) provide identical or superior efficacy to diphenhydramine with essentially zero anticholinergic burden — no dementia risk, no sedation, no urinary retention. For sleep, CBT-I (Cognitive Behavioral Therapy for Insomnia) outperforms any sleep medication in head-to-head trials at 12 months.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Loratadine (Claritin, 10mg/day) — for allergies
Second-generation H1 antihistamine; does not cross blood-brain barrier; no anticholinergic activity
Equal efficacy to diphenhydramine for allergic rhinitis without sedation, cognitive impairment, or dementia risk; preferred by NICE, NHS, and AGS Beers criteria for all adults, especially elderly
Cetirizine (Zyrtec, 10mg/day) — for allergies
Second-generation; slightly more sedating than loratadine but far less than diphenhydramine; no anticholinergic burden
Slightly faster onset than loratadine (1 hour vs. 1–3 hours); preferred for acute allergic reactions when speed matters
Melatonin (0.5–1mg, 30 minutes before bed) — for sleep
Physiological dose — NOT the 5–10mg typically sold OTC. Lower doses (0.5–1mg) match or exceed efficacy of higher doses for sleep onset
Reduces sleep onset time without disrupting REM sleep architecture (unlike diphenhydramine); no anticholinergic effects; no tolerance development; safe long-term
CBT-I (Cognitive Behavioral Therapy for Insomnia)
Sleep restriction, stimulus control, cognitive restructuring — not a pill
Head-to-head vs. zolpidem (Ambien): CBT-I produced greater sleep improvements at both post-treatment and 12-month follow-up. Effective for 70–80% of chronic insomnia patients. No side effects.
Magnesium glycinate (300–400mg before bed)
Most bioavailable magnesium form; supports GABA and melatonin pathways
Reduces sleep onset time and improves sleep quality in magnesium-insufficient adults (common); no anticholinergic effects; mild muscle-relaxing properties
Key Studies
Global Prescribing & Pricing
The US is the primary OTC market for diphenhydramine sleep products; UK NHS actively advises switching to second-generation antihistamines; Australia has stronger pharmacist gatekeeping
United States
$4–12 (OTC)/mo
Diphenhydramine products marketed heavily as OTC sleep aids (ZzzQuil, Unisom, Tylenol PM, Advil PM); no anticholinergic dementia warning on packaging
FDA has not required anticholinergic dementia risk labeling despite multiple expert panels raising concerns; 1946 approval grandfathered; pharmacists not required to counsel
OTC — no prescription; no pharmacist counseling required
United Kingdom
~$3–8/mo
NHS recommends switching from diphenhydramine to loratadine or cetirizine; NHS website explicitly states older antihistamines are "generally not recommended for long-term use"
NICE guidance strongly favors non-sedating antihistamines; community pharmacists encouraged to recommend switch; no OTC sleep-aid marketing comparable to US
OTC; pharmacists typically recommend second-gen alternatives
Germany
~$4–10/mo
G-BA and German pharmacists more actively counsel patients toward non-sedating options; advertising restrictions prevent aggressive OTC sleep marketing
Pharmacists legally required to provide consultation at point of sale; anticholinergic risks discussed; sleep hygiene resources provided
OTC; pharmacist counseling mandated
Australia
~$4–10/mo
TGA has reviewed diphenhydramine for OTC status; pharmacist consultation required for purchase; strong messaging toward loratadine/cetirizine for ongoing allergy
OTC access via pharmacist only (Schedule 2/3); explicit recommendation in TGA guidance for elderly to avoid; anticholinergic risk noted in product information
OTC via pharmacist with mandatory counseling
Japan
~$5–12/mo
Available OTC in lower doses; pharmacist required for dispensing; prescribing culture favors lower doses and shorter courses than US
Consumer advertising restrictions; pharmacist must provide written information sheet at sale; elderly counseling includes explicit cognitive risk warning
Pharmacist-supervised OTC
The US allows diphenhydramine to be marketed as a sleep aid in brightly packaged products alongside pain relievers — with no anticholinergic dementia warning on the box. The UK's NHS website tells patients to switch to loratadine. Germany requires pharmacist counseling at point of purchase. The 1946 grandfathered approval means this drug has never faced modern safety requirements — it would likely carry a black box warning if submitted today.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
The 1946 FDA approval predates modern clinical trial requirements — diphenhydramine has never undergone the rigorous randomized controlled trial programme required of drugs approved today. The Gray et al. 2015 dementia study was funded by NIH and the NIA — independently of industry. The original approval trials were minimal by today's standards. Post-marketing studies are largely academic and independent, not industry-funded.
Declared Conflicts of Interest
Diphenhydramine generates significant revenue across multiple OTC categories (allergy, sleep, combination products). J&J, Pfizer (Advil PM), and P&G have financial interest in its continued OTC status. Regulatory inertia means the original 1946 approval standards are grandfathered — this drug would likely face a much more restrictive evaluation if submitted for approval today. The FDA has not acted on the growing dementia evidence despite its own expert advisory panels discussing the anticholinergic risk.
Key Efficacy Results
Gray et al. 2015: 54% increased dementia risk with cumulative strong anticholinergic use over 10 years; association did not reverse after drug cessation. Sleep tolerance: efficacy as sleep aid gone by night 3–4 in most users. Richardson 2018: confirmed dementia association in UK Biobank cohort.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Diphenhydramine HCl. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Diphenhydramine HCl in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| Gray et al. — Anticholinergic Burden & Dementia (JAMA IM 2015) | PMID:25621434 | |
| Richardson et al. — Anticholinergic Drugs & Dementia (JAMA IM 2018) | PMID:29450480 | |
| Diphenhydramine Sleep Tolerance Study | PMID:25521196 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Diphenhydramine does not cause true physiological dependence, but if used nightly for sleep, stopping abruptly can cause 1–3 nights of worse sleep (rebound insomnia) as the CNS readjusts. This is not dangerous — it is expected. Start melatonin 0.5mg the same night you stop.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·For allergy management, research supports switching to loratadine 10mg or cetirizine 10mg — no taper is documented as needed
- ·For sleep use, research supports transitioning to melatonin 0.5–1mg; sleep hygiene improvements are well-documented as effective simultaneously
- ·Research documents 1–3 nights of slightly poorer sleep during transition — this is a documented pharmacological rebound effect, not physical dependence
- ·CBT-I (Cognitive Behavioral Therapy for Insomnia) has strong documented evidence as an approach to begin alongside stopping diphenhydramine
Warning Symptoms — Contact Your Doctor If You Experience:
- Inability to urinate — stop immediately and seek emergency care
- Confusion, agitation, or hallucinations in elderly — anticholinergic delirium; stop and seek medical care
- Rapid heartbeat (tachycardia) — anticholinergic toxicity; seek care
- Severe eye pain with blurred vision — possible glaucoma crisis; stop and seek emergency care
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.I'm over 65 and use Benadryl or ZzzQuil regularly — can we discuss switching to loratadine for allergies and melatonin for sleep?
- 2.Do I have any other anticholinergic medications in my regimen that might be adding up to a cumulative burden?
- 3.I have a family history of Alzheimer's — should I be completely avoiding anticholinergic drugs?
- 4.I use diphenhydramine for sleep — can we discuss CBT-I or melatonin as alternatives?
- 5.I have an enlarged prostate — is there a risk of urinary retention with this?
Lab Tests to Request
- Anticholinergic Cognitive Burden (ACB) scale — ask your pharmacist to review your full medication list
- MoCA or MMSE (brief cognitive screen) if using long-term and have memory concerns
- Post-void residual ultrasound if urinary retention symptoms appear
- CBC if using chronically (mild anemia possible)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Benadryl® / ZzzQuil® / Unisom®
- What is Benadryl® / ZzzQuil® / Unisom® used for?
- Benadryl® / ZzzQuil® / Unisom® (Diphenhydramine HCl) is a First-Generation Antihistamine / Anticholinergic manufactured by J&J (Benadryl) / Procter & Gamble (ZzzQuil) / Chattem (Unisom) / Generic. FDA-approved indications include: Allergic rhinitis (hay fever); Urticaria (hives); Anaphylaxis adjunct (not primary treatment — epinephrine is); Motion sickness; OTC sleep aid (short-term only).
- What are the common side effects of Benadryl® / ZzzQuil® / Unisom®?
- Common side effects of Benadryl® / ZzzQuil® / Unisom® include: Sedation / drowsiness (70%+); Dry mouth (35%+); Urinary retention (High in men with BPH); Constipation (20%); Blurred vision (10–15%).
- How much does Benadryl® / ZzzQuil® / Unisom® cost?
- Benadryl® / ZzzQuil® / Unisom® list price is approximately $5–12. With insurance it typically costs $3–10 (OTC); without insurance approximately $3–10 (OTC).
- Who funded the clinical trials for Benadryl® / ZzzQuil® / Unisom®?
- The 1946 FDA approval predates modern clinical trial requirements — diphenhydramine has never undergone the rigorous randomized controlled trial programme required of drugs approved today. The Gray et al. 2015 dementia study was funded by NIH and the NIA — independently of industry. The original approval trials were minimal by today's standards. Post-marketing studies are largely academic and independent, not industry-funded.
- How strong is the clinical evidence for Benadryl® / ZzzQuil® / Unisom®?
- Key studies: Gray et al. (JAMA Internal Medicine 2015) — anticholinergic burden & dementia; tolerance studies showing sleep efficacy gone by night 3–4. Gray et al. 2015: 54% increased dementia risk with cumulative strong anticholinergic use over 10 years; association did not reverse after drug cessation. Sleep tolerance: efficacy as sleep aid gone by night 3–4 in most users. Richardson 2018: confirmed dementia association in UK Biobank cohort. Potential conflicts of interest: Diphenhydramine generates significant revenue across multiple OTC categories (allergy, sleep, combination products). J&J, Pfizer (Advil PM), and P&G have financial interest in its continued OTC status.
- Are there non-drug alternatives to Benadryl® / ZzzQuil® / Unisom®?
- For allergies, second-generation antihistamines (loratadine, cetirizine, fexofenadine) provide identical or superior efficacy to diphenhydramine with essentially zero anticholinergic burden — no dementia risk, no sedation, no urinary retention. For sleep, CBT-I (Cognitive Behavioral Therapy for Inso See the Alternatives tab for full details.
Get notified when we update Benadryl® / ZzzQuil® / Unisom®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.